Canada Markets closed

Curis, Inc. (CRIS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.2700+0.2000 (+6.51%)
At close: 04:00PM EST
3.2700 0.00 (0.00%)
After hours: 04:47PM EST
Sign in to post a message.
  • P
    Peter
    Just what was the point of the Wainwright presentation this morning at 7:00 a.m. taped on some other day and introduced by someone who gave the appearance of being intern. And then CEO repeats same thing he has been saying for the last year about how CEO stumbled upon CA-4948 as a possible kinase inhibitor of IRAK-4 L, a mutation found in AML/MDS patients. On and on he drones, no questions just reading into a recorder. Does he get paid by the number of presentations he makes. Plus percentages of CRs etc going down as population of patients expand. Maybe by the time they get a large enough sample size, the percentage will be down to 22% about where CA-170 was when they had to inform shareholders not high enough to ask for fast track approval. What was Raymond James thinking when it recommended when SP was at $7 that stock would go to $15. Does State Street which holds 8% of stock really make money off its acquisiton by lending shares to investors shorting the stock?
  • P
    Phil
    Curis is not being destroyed like the rest of Nasdaq. (Strong) buy signal?
  • b
    bostonchicken99
    Retail shorts getting shaken out, that's it.
  • f
    frank
    Last time there was good news price dropped to around $1.16, then did a 10-15x to $17+. Can history repeat itself?
  • P
    Peter
    Ok Curis plans to release Ph2 update on its monotherapy CA-4984 trial this month regarding the sub-population of AML patients with spliceosome mutations and those with FLT3 mutations. With regard to the former, the initial data showed 3 patients having a CR and the latter, one patient having a CR.
    My understanding is that Cris expects/hopes to report that data will show up to 9 or 10 patients with a CR out of 20 in the spliceosome populations. That would be good news. Why would they be hiring three new high-level professionals if they did not believe the data release would be positive?
  • P
    PJ
    One thing investors have to realize. The stock has a very large institutional holding by a venerable Who’s Who of healthcare hedge funds. Always follow the money and invest in companies have huge investments by these companies that are in the know. This is a solid stock people
  • P
    Peter
    Okay they are presenting on January 10th. Surely they are not going to show up at the conference without having released the interim ph2 update they have been promising since October.
  • P
    Peter
    Curis reverting to form, like CA-170 investors will be on tenterhooks waiting and hoping for the day when FDA agrees to fast track the mono-therapy trial for CA-4984. Listening to the dog and pony show, you really got the impression that someone needed to take them over. Too bad Roche did not take them over; Curis sold out for the licensing agreement. Maybe CA-4948 will give them more leverage, it seems to have the potential to be a blockbuster which Erivedge never did.
  • K
    Kathryn E
    Why is this stock down 28% today????
  • s
    shalom
    jeebus cribs they run it up and run it right back down
  • b
    bostonchicken99
    They are trying to dump Curis.
  • t
    tommie
    less than 8 months of cash left.
  • b
    bostonchicken99
    Zacks changed their rank from a buy to a sell, that quick. Long term sell.
  • Y
    Yahoo Finance Insights
    Curis reached a 52 Week low at 3.10
  • g
    golong
    As a former $CRIS investor, left it a few years ago to go to $SCYX. Blockbuster drug classification and great upside potential.
  • P
    Peter
    after the January update misfire, when is the next catalyst? 2023
  • P
    PJ
    Bought back in today, last sold at $14+ when the stock ran to $16 earlier this year. This is way oversold and those doubting--look at the institutional holdings and those holding. A who's who of health-care hedge funds. This is a $12 stock in 12 months, maybe higher. I might up my position as it continues to rise.
  • b
    bostonchicken99
    Short squeeze coming !
  • J
    Joe
    Good bye yellow brick road....
  • s
    shalom
    I just listened to the presentation. the data is good! #$%$ORR went down a bit but with more patients, it may go up again.also these patients were heavily pretreated relapsed refractory populationdrug is very safe at RPT dose 300 mgand they have shown they can control side effects of vistaI hate to sound like a tin foil hat stop the steal flat earther but I think the price dive is from market manipulation to void all the call options that were sold in the last few months. the market makers want those options to expire worthless so they are shorting the #$%$ out of this stock.pretty depressing but that's my take.